KALY Receives $0.05 Price Target From Goldman Small Cap RSRCH
=====================
Kali, Inc. ( KALY )
Alert Price: $0.01
Float: 6.74M (OTC Markets)
Website | Recent News
========================
The CBD sector just got a huge endorsement from one of pro sport's biggest personalities.
Former Super Bowl-winning tight end, Rob Gronkowski, is the latest ex-athlete to step into the cannabis industry.
During a press conference held in New York City on Monday, Gronk announced that he's partnering with Abacus Health Products and its line of topical CBD products called CBDMEDIC. Little is known about his deal with Abacus Health Products, but according to NFL Network's Ian Rapoport, Gronkowski's goal is to advocate for the legalization of CBD products by professional sports leagues.
"I’m here to appeal to the sports governing bodies to update their positions on CBD used by all players," Gronk told the audience. "For the first time in a decade, I’m pain-free."
Today's news should give the entire CBD sector a nice lift, and one company that could benefit is KALY .
The last time we brought KALY to your attention shares ran up from $0.009 to a high of $0.185 for a single session gain of +105%.
KALY is now trading back at a highly attractive price of $0.01 per share, and we're betting on another run-up this week.
Here's why...
KALY- Kali-Extracts Announces New Analyst Report Speculating $0.05 PPS Following Recent Biopharmaceutical Cannabis Extract Updates
finance.yahoo.com/news/kaly-kali...
Moments ago, KALY announced a new analyst report covering the company’s recent biopharmaceutical cannabis extract business development updates. The report has been released by Goldman Small Cap Research after market today, August 27, 2019, and can be found on Goldman’s website www.goldmanresearch.com. The report speculates a potential KALY price per share of $0.05.
“Already generating major revenue growth and operating profit, a series of near-term revenue and pharmaceutical development milestones by KALY warrant a closer look by investors as these shares could trade to the $0.05 level in the near term.”
The analyst report update initiative was triggered by KALY’s recent CEO update on the company’s cannabis extract biopharmaceutical business pursuing $170 billion in pharmaceutical treatments where the CEO announced new patent and trademark applications on KALY’s CBD Formulation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The report includes coverage on the impact of the company’s recently announced CBD extraction contracts with hemp farming operations worth $15 million, and coverage of the company’s recently posted 2019 YTD financials reporting 250% revenue growth. The analyst report also addresses KALY’s ongoing business partnership with Puration , Inc. ( PURA ) and the sales of KALY’s Hemp4mula CBD candy line through North American Cannabis Holdings, Inc’s ( USMJ ) ecommerce site www. usmj .com.
“When we last left Kali, Inc. (OTC – KALY – NR ) dba/Kali-Extracts, Inc. in January 2019, the Company was full of promise and in our view, well-positioned to emerge as a future leader in its key segments of the CBD arena. Seven months later, KALY has dramatically exceeded our expectations with respect to revenue and new business, along with product development and its overall industry positioning. The successes on the product development and commercialization fronts appear to serve as potential catalysts to favourably impact KALY’s stock and valuation, thus affirming the value of its current and future IP .”
To view the full report visit www.goldmanresearch.com/
To learn more about the company visit www.kali-extracts.com/
KALY Sees 250% Revenue Growth From New Cannabis Business With Even More Dramatic Growth Anticipated In Second Half Of 2019
finance.yahoo.com/news/kaly-kali...
• KALY 1st Six Months 2019 Revenue Is $165,000 Compared To $46,000 Last Year
• KALY Also Reported $70,000 Operating Net Income 1st Six Months 2019
• 250% Revenue Growth Results From Q4 2018 Cannabis Business Acquired Q4 2018
• KALY Owns And Operates Patented Cannabis Extraction Process And Has Filed For A Second Patent On A New Biopharmaceutical CBD Formulation
• Hemp Farming CBD Extraction Contracts Anticipated To Result In Even More Dramatic Revenue Growth In Second Half Of 2019
• KALY Plans To Publish Website Tomorrow Dedicated To New CBD Formulation And Corresponding Patent Application
• KALY Anticipates An Analyst Update To Be Published On The Company Next Week
Last week, KALY announced the publishing of its up-to-date corporate financials through the end of Q2 2019. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company’s cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY’s new cannabis business has seen the company’s revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY also realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
Earlier this week, KALY announced filing a new patent application specifically on its formulation for symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s existing patented cannabis extraction process. The company has also filed to register a trademark on the name RESPRX as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. KALY plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RESPRX, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RESPRX website to be published Friday will include details on KALY’s recent patent and trademark applications for the RESPRX CBD formulation.
KALY has implemented a long-term sustainable overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. KALY , through partnership and independently, has also introduced to market a number of CBD infused consumer food products. The revenue realized in the first six months of 2019 comes primarily from KALY’s various CBD infusion offerings.
Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations. KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
KALY management is committed to providing timely disclosures consistent with OTC Markets’ Pink Current Information Alternative Reporting Standard. Shortly after executing the acquisition of NCMB and implementing a cannabis business shift, OTC Markets implemented a buyer beware flag urging caution in regard to a KALY investment. KALY management continues to work toward resolving the concerns that resulted in the flag. In the meantime, KALY management has published an alternative disclosure site in order to provide timely disclosures of the most up-to-date corporate information. The up-to-date corporate financial information referenced in this release can be found on the company’s alternative disclosure site – www.kaly-info.com.
At just one-cent per share, KALY Leads in CBD ‘Boom’ Market and Stands Ready For Follow on US Marijuana Legalization
The rise of the marijuana industry over the past several years has been monumental, and 2018 in particular was ground breaking for cannabis-related businesses. After watching for years as individual U.S. states legalized marijuana one by one for various purposes, the entire nation of Canada took a great leap forward by making recreational cannabis legal across the country in mid-October. Gradually, more jurisdictions across the globe have decided to eliminate laws against marijuana, and the movement seems to be gaining even more momentum in 2019.
The Cannabis ETF (THCX), the first passively managed pure-play ETF solution for investing in cannabis, is now available to investors. The Cannabis ETF comes from Innovation Shares, a sponsor of unique thematic exchange traded funds. At the same time the cannabis pure play ETF was launched, the US House of Representatives began discussing the Federal Legalization of Marijuana.
KALY management views KALY’s strategy as an optimal fit into the cannabis investment opportunity reflected by the THCX launch and Federal Legalization of Marijuana discussion.
The Bullish Case For KALY:
• KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.
• The company is currently developing Cannabis Extract Biopharmaceutical Therapies targeting $170 billion in market potential.
• KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time provide KALY with the long-term staying power to bring its cannabis extract biopharmaceutical products to market.
• Kali-Extracts Mobile CBD Extraction Is A Service In High Demand And Could Blow By $20 Million Revenue Target
• Has announced $15 million in hemp derived CBD extraction contracts.
• Management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer.
• Plans to Add CBD Infused Coffee , Tea, and Beer to List of New Developments
KALY Confirms Cannabis Biopharmaceutical Update Targeting $170 Billion Market
Kali-Extracts Announces RESPRX CBD Formulation For Symptoms Associated With COPD – A $14 Billion Market Opportunity
finance.yahoo.com/news/kaly-kali...
• KALY Develops COPD Treatment CBD Formulation from Its Patented Extraction Process
• KALY Files New Patent Application on Its CBD Formulation for the Treatment of COPD
• KALY Files Trademark Registration on RESPRX Brand Name for COPD Treatment
• Market for COPD Treatment Anticipated to Reach $14 Billion
• KALY to File Up-To-Date Corporate Financials on Thursday This Week
• KALY to Publish RESPRX Website with Patent and Trademark Details on Friday
Last week KALY released an update from CEO Frederick Ferri on the company’s ongoing Cannabis Extract Biopharmaceutical developments. KALY owns and operates a U.S. Patent for cannabis extraction. The update today highlights the company’s CBD formulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s patented cannabis extraction process. In conjunction with the research already conducted and the next phase of research now moving forward, KALY today announces the filing of a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also announces the filing of a trademark on the name RESPRX as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025. In addition to the further updates included in the narrative herein to follow, KALY plans to release additional corporate information later this week on Thursday, August 22nd. On Friday, August 23rd, KALY plans to publish a website specifically dedicated to detailed information on RESPRX.
CEO Fredrick Ferri’s Comprehensive Update:
Over four years ago, I founded Nature Comfort Meds to develop various therapies from cannabis extracts to treat specific health issues. The company transformed into what was later called NCM Biotech (NCMB). In the fourth quarter of last year, 2018, KALY acquired NCMB. In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In addition to the research already published on the company’s CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions, KALY has initiated a next stage of clinical development and testing for its COPD therapy. KALY is also currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
As already mentioned above, the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions is clearly unique and the testing to date has demonstrated sufficient efficacy to warrant our patent protection. Accordingly, on behalf of the company, I have filed for a patent on the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions. I have also filed for a trademark registration on the name RESPRX to delineate a brand name for the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions.
KALY has announced $15 million in hemp derived CBD extraction contracts. KALY is leveraging its US Patented cannabis extraction process to establish a leadership position in the booming CBD market. At the same time KALY is prepared to leverage its US Patented cannabis extraction process within the inevitably legalized US recreational marijuana market.
A CNBC article reporting on the US House of Representatives discussion on the Legalization of Marijuana Federally, commented that, “Eleven states have legalized adult recreational use and a majority of Americans support legalization.”
KALY Pharmaceutical Business and PURA and USMJ Partnerships
KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. Drawing on KALY’s patented cannabis extraction expertise, in addition to winning the $5 million extraction contract mentioned above, KALY has partnered with Puration , Inc. ( PURA ) to lend its extraction expertise in the production of EVERx CBD Sports Water, the leading CBD infused beverage for the sports nutrition market. KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way. Hemp4mula is available on the Ecommerce site USMJ .com hosted by North American Cannabis Holdings, Inc. ( aka USMJ ) ( USMJ ). KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time provide KALY with the long-term staying power to bring its cannabis extract biopharmaceutical products to market.
Kali-Extracts Mobile CBD Extraction Is A Service In High Demand And Could Blow By $20 Million Revenue Target
In late July, KALY management confirmed a growing market interest in the company’s mobile CBD extraction service. KALY owns and operates a U.S. Patented Cannabis Extraction Process. The company recently announced building its Patented extraction process into a mobile unit to provide onsite hemp extraction. The company has announced $15 million worth of CBD extraction contracts so far and a target $20 million in 2019 revenue. With harvest season fast approaching, KALY’s mobile extraction unit will soon hit the road and the potential orders for KALY’s CBD extraction service are stacking up. The company anticipates announcing new contracts soon.
KALY recently published a management overview on the company’s mobile cannabis extraction capacity. See the full presentation: www.kali-extracts.com/extraction...
Kali-Extracts Mobile Cannabis Extraction Capacity
KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.
With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. KALY , through partnership and independently, has also introduced to market a number of CBD infused consumer food products. Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.
KALY anticipates a dramatic revenue increase in the second half of 2019
KALY management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer. So far, KALY has announced two contracts to extract CBD from hemp worth a total combined potential of $15 million. Management has set a target to sign $20 million in CBD extraction contracts this year. Additional CBD extraction contracts are in the works. The company plans to self-disclose current financials through the second quarter of 2019 next week. Current revenues are derived from the sale of the company’s own CBD infused candies and the company’s licensing of its patented cannabis extraction process. The addition of revenue from the extraction of CBD from upcoming hemp harvests is anticipated to dramatically increase revenue in the second half of 2019.
KALY Adds CBD Infused Coffee , Tea, and Beer to List of New Developments
Two weeks ago, PURA and KALY confirmed adding CBD infused tea to its new line of CBD beverage partnerships. Last week, PURA and KALY published a management presentation to provide shareholders with more details on PURA’s recently implemented program to introduce CBD infused versions of existing third-party beverages. PURA has recently announced plans to introduce a CBD infused beer in partnership with an existing beer producer. In similar fashion, PURA is partnering with an existing coffee producer to introduce a CBD infused coffee . In conjunction with the presentation published last week, PURA announced a third partnership to develop CBD infused tea. Additional partnerships are in the works. PURA is a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year. PURA has targeted $4 million in sales for 2019. The presentation is included in its entirety on the company’s website.
About Kali, Inc. ( KALY )
KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign for KALY which includes up to 5,000 investor views. We have previously been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign for KALY which included up to 5,000 investor views -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Kali, Inc. ( KALY )
Alert Price: $0.01
Float: 6.74M (OTC Markets)
Website | Recent News
========================
The CBD sector just got a huge endorsement from one of pro sport's biggest personalities.
Former Super Bowl-winning tight end, Rob Gronkowski, is the latest ex-athlete to step into the cannabis industry.
During a press conference held in New York City on Monday, Gronk announced that he's partnering with Abacus Health Products and its line of topical CBD products called CBDMEDIC. Little is known about his deal with Abacus Health Products, but according to NFL Network's Ian Rapoport, Gronkowski's goal is to advocate for the legalization of CBD products by professional sports leagues.
"I’m here to appeal to the sports governing bodies to update their positions on CBD used by all players," Gronk told the audience. "For the first time in a decade, I’m pain-free."
Today's news should give the entire CBD sector a nice lift, and one company that could benefit is KALY .
The last time we brought KALY to your attention shares ran up from $0.009 to a high of $0.185 for a single session gain of +105%.
KALY is now trading back at a highly attractive price of $0.01 per share, and we're betting on another run-up this week.
Here's why...
KALY- Kali-Extracts Announces New Analyst Report Speculating $0.05 PPS Following Recent Biopharmaceutical Cannabis Extract Updates
finance.yahoo.com/news/kaly-kali...
Moments ago, KALY announced a new analyst report covering the company’s recent biopharmaceutical cannabis extract business development updates. The report has been released by Goldman Small Cap Research after market today, August 27, 2019, and can be found on Goldman’s website www.goldmanresearch.com. The report speculates a potential KALY price per share of $0.05.
“Already generating major revenue growth and operating profit, a series of near-term revenue and pharmaceutical development milestones by KALY warrant a closer look by investors as these shares could trade to the $0.05 level in the near term.”
The analyst report update initiative was triggered by KALY’s recent CEO update on the company’s cannabis extract biopharmaceutical business pursuing $170 billion in pharmaceutical treatments where the CEO announced new patent and trademark applications on KALY’s CBD Formulation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The report includes coverage on the impact of the company’s recently announced CBD extraction contracts with hemp farming operations worth $15 million, and coverage of the company’s recently posted 2019 YTD financials reporting 250% revenue growth. The analyst report also addresses KALY’s ongoing business partnership with Puration , Inc. ( PURA ) and the sales of KALY’s Hemp4mula CBD candy line through North American Cannabis Holdings, Inc’s ( USMJ ) ecommerce site www. usmj .com.
“When we last left Kali, Inc. (OTC – KALY – NR ) dba/Kali-Extracts, Inc. in January 2019, the Company was full of promise and in our view, well-positioned to emerge as a future leader in its key segments of the CBD arena. Seven months later, KALY has dramatically exceeded our expectations with respect to revenue and new business, along with product development and its overall industry positioning. The successes on the product development and commercialization fronts appear to serve as potential catalysts to favourably impact KALY’s stock and valuation, thus affirming the value of its current and future IP .”
To view the full report visit www.goldmanresearch.com/
To learn more about the company visit www.kali-extracts.com/
KALY Sees 250% Revenue Growth From New Cannabis Business With Even More Dramatic Growth Anticipated In Second Half Of 2019
finance.yahoo.com/news/kaly-kali...
• KALY 1st Six Months 2019 Revenue Is $165,000 Compared To $46,000 Last Year
• KALY Also Reported $70,000 Operating Net Income 1st Six Months 2019
• 250% Revenue Growth Results From Q4 2018 Cannabis Business Acquired Q4 2018
• KALY Owns And Operates Patented Cannabis Extraction Process And Has Filed For A Second Patent On A New Biopharmaceutical CBD Formulation
• Hemp Farming CBD Extraction Contracts Anticipated To Result In Even More Dramatic Revenue Growth In Second Half Of 2019
• KALY Plans To Publish Website Tomorrow Dedicated To New CBD Formulation And Corresponding Patent Application
• KALY Anticipates An Analyst Update To Be Published On The Company Next Week
Last week, KALY announced the publishing of its up-to-date corporate financials through the end of Q2 2019. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company’s cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY’s new cannabis business has seen the company’s revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY also realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
Earlier this week, KALY announced filing a new patent application specifically on its formulation for symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s existing patented cannabis extraction process. The company has also filed to register a trademark on the name RESPRX as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. KALY plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RESPRX, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RESPRX website to be published Friday will include details on KALY’s recent patent and trademark applications for the RESPRX CBD formulation.
KALY has implemented a long-term sustainable overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. KALY , through partnership and independently, has also introduced to market a number of CBD infused consumer food products. The revenue realized in the first six months of 2019 comes primarily from KALY’s various CBD infusion offerings.
Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations. KALY management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.
KALY management is committed to providing timely disclosures consistent with OTC Markets’ Pink Current Information Alternative Reporting Standard. Shortly after executing the acquisition of NCMB and implementing a cannabis business shift, OTC Markets implemented a buyer beware flag urging caution in regard to a KALY investment. KALY management continues to work toward resolving the concerns that resulted in the flag. In the meantime, KALY management has published an alternative disclosure site in order to provide timely disclosures of the most up-to-date corporate information. The up-to-date corporate financial information referenced in this release can be found on the company’s alternative disclosure site – www.kaly-info.com.
At just one-cent per share, KALY Leads in CBD ‘Boom’ Market and Stands Ready For Follow on US Marijuana Legalization
The rise of the marijuana industry over the past several years has been monumental, and 2018 in particular was ground breaking for cannabis-related businesses. After watching for years as individual U.S. states legalized marijuana one by one for various purposes, the entire nation of Canada took a great leap forward by making recreational cannabis legal across the country in mid-October. Gradually, more jurisdictions across the globe have decided to eliminate laws against marijuana, and the movement seems to be gaining even more momentum in 2019.
The Cannabis ETF (THCX), the first passively managed pure-play ETF solution for investing in cannabis, is now available to investors. The Cannabis ETF comes from Innovation Shares, a sponsor of unique thematic exchange traded funds. At the same time the cannabis pure play ETF was launched, the US House of Representatives began discussing the Federal Legalization of Marijuana.
KALY management views KALY’s strategy as an optimal fit into the cannabis investment opportunity reflected by the THCX launch and Federal Legalization of Marijuana discussion.
The Bullish Case For KALY:
• KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.
• The company is currently developing Cannabis Extract Biopharmaceutical Therapies targeting $170 billion in market potential.
• KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time provide KALY with the long-term staying power to bring its cannabis extract biopharmaceutical products to market.
• Kali-Extracts Mobile CBD Extraction Is A Service In High Demand And Could Blow By $20 Million Revenue Target
• Has announced $15 million in hemp derived CBD extraction contracts.
• Management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer.
• Plans to Add CBD Infused Coffee , Tea, and Beer to List of New Developments
KALY Confirms Cannabis Biopharmaceutical Update Targeting $170 Billion Market
Kali-Extracts Announces RESPRX CBD Formulation For Symptoms Associated With COPD – A $14 Billion Market Opportunity
finance.yahoo.com/news/kaly-kali...
• KALY Develops COPD Treatment CBD Formulation from Its Patented Extraction Process
• KALY Files New Patent Application on Its CBD Formulation for the Treatment of COPD
• KALY Files Trademark Registration on RESPRX Brand Name for COPD Treatment
• Market for COPD Treatment Anticipated to Reach $14 Billion
• KALY to File Up-To-Date Corporate Financials on Thursday This Week
• KALY to Publish RESPRX Website with Patent and Trademark Details on Friday
Last week KALY released an update from CEO Frederick Ferri on the company’s ongoing Cannabis Extract Biopharmaceutical developments. KALY owns and operates a U.S. Patent for cannabis extraction. The update today highlights the company’s CBD formulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s patented cannabis extraction process. In conjunction with the research already conducted and the next phase of research now moving forward, KALY today announces the filing of a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also announces the filing of a trademark on the name RESPRX as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025. In addition to the further updates included in the narrative herein to follow, KALY plans to release additional corporate information later this week on Thursday, August 22nd. On Friday, August 23rd, KALY plans to publish a website specifically dedicated to detailed information on RESPRX.
CEO Fredrick Ferri’s Comprehensive Update:
Over four years ago, I founded Nature Comfort Meds to develop various therapies from cannabis extracts to treat specific health issues. The company transformed into what was later called NCM Biotech (NCMB). In the fourth quarter of last year, 2018, KALY acquired NCMB. In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In addition to the research already published on the company’s CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions, KALY has initiated a next stage of clinical development and testing for its COPD therapy. KALY is also currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
As already mentioned above, the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions is clearly unique and the testing to date has demonstrated sufficient efficacy to warrant our patent protection. Accordingly, on behalf of the company, I have filed for a patent on the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions. I have also filed for a trademark registration on the name RESPRX to delineate a brand name for the CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions.
KALY has announced $15 million in hemp derived CBD extraction contracts. KALY is leveraging its US Patented cannabis extraction process to establish a leadership position in the booming CBD market. At the same time KALY is prepared to leverage its US Patented cannabis extraction process within the inevitably legalized US recreational marijuana market.
A CNBC article reporting on the US House of Representatives discussion on the Legalization of Marijuana Federally, commented that, “Eleven states have legalized adult recreational use and a majority of Americans support legalization.”
KALY Pharmaceutical Business and PURA and USMJ Partnerships
KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. Drawing on KALY’s patented cannabis extraction expertise, in addition to winning the $5 million extraction contract mentioned above, KALY has partnered with Puration , Inc. ( PURA ) to lend its extraction expertise in the production of EVERx CBD Sports Water, the leading CBD infused beverage for the sports nutrition market. KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way. Hemp4mula is available on the Ecommerce site USMJ .com hosted by North American Cannabis Holdings, Inc. ( aka USMJ ) ( USMJ ). KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time provide KALY with the long-term staying power to bring its cannabis extract biopharmaceutical products to market.
Kali-Extracts Mobile CBD Extraction Is A Service In High Demand And Could Blow By $20 Million Revenue Target
In late July, KALY management confirmed a growing market interest in the company’s mobile CBD extraction service. KALY owns and operates a U.S. Patented Cannabis Extraction Process. The company recently announced building its Patented extraction process into a mobile unit to provide onsite hemp extraction. The company has announced $15 million worth of CBD extraction contracts so far and a target $20 million in 2019 revenue. With harvest season fast approaching, KALY’s mobile extraction unit will soon hit the road and the potential orders for KALY’s CBD extraction service are stacking up. The company anticipates announcing new contracts soon.
KALY recently published a management overview on the company’s mobile cannabis extraction capacity. See the full presentation: www.kali-extracts.com/extraction...
Kali-Extracts Mobile Cannabis Extraction Capacity
KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.
With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. KALY , through partnership and independently, has also introduced to market a number of CBD infused consumer food products. Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.
KALY anticipates a dramatic revenue increase in the second half of 2019
KALY management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer. So far, KALY has announced two contracts to extract CBD from hemp worth a total combined potential of $15 million. Management has set a target to sign $20 million in CBD extraction contracts this year. Additional CBD extraction contracts are in the works. The company plans to self-disclose current financials through the second quarter of 2019 next week. Current revenues are derived from the sale of the company’s own CBD infused candies and the company’s licensing of its patented cannabis extraction process. The addition of revenue from the extraction of CBD from upcoming hemp harvests is anticipated to dramatically increase revenue in the second half of 2019.
KALY Adds CBD Infused Coffee , Tea, and Beer to List of New Developments
Two weeks ago, PURA and KALY confirmed adding CBD infused tea to its new line of CBD beverage partnerships. Last week, PURA and KALY published a management presentation to provide shareholders with more details on PURA’s recently implemented program to introduce CBD infused versions of existing third-party beverages. PURA has recently announced plans to introduce a CBD infused beer in partnership with an existing beer producer. In similar fashion, PURA is partnering with an existing coffee producer to introduce a CBD infused coffee . In conjunction with the presentation published last week, PURA announced a third partnership to develop CBD infused tea. Additional partnerships are in the works. PURA is a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year. PURA has targeted $4 million in sales for 2019. The presentation is included in its entirety on the company’s website.
About Kali, Inc. ( KALY )
KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign for KALY which includes up to 5,000 investor views. We have previously been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign for KALY which included up to 5,000 investor views -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media